期刊全名
Therapeutic Innovation & Regulatory Science
最新影响因子
1.9年均收录文章
94期刊简称
THER INNOV REGUL SCI来源地区
UNITED STATES详细类别
MEDICAL INFORMATICS医学：信息
4区
PHARMACOLOGY & PHARMACY药学
4区
中科院杂志分区
医学(4区)是否OA开放访问
No投稿难度
出版周期
投稿链接
点击投稿杂志主页
点击查看杂志主页自引率
17.40%类别
MEDICAL INFORMATICS-PHARMACOLOGY & PHARMACYcoverage
Science Citation Index Expanded审稿周期
Therapeutic Innovation & Regulatory Science是一本国际学术期刊，ISSN号为2168-4790，由Springer出版，出版地为美国，出版周期为双月刊。该期刊的影响因子根据年份有所不同，最新数据需查询官方来源，非开放获取（OA）期刊，已被SCI收录，中科院分区情况需参考最新分区表。该期刊专注于药物开发、监管科学和医疗产品创新领域，发文特点包括临床试验设计、法规政策、药物安全与疗效评估等研究。杂志质量较高，注重学术严谨性，但因涉及监管政策，部分研究可能受地域性限制，投稿时需注意研究内容的全球适用性。总体而言，该期刊是药物开发与监管科学领域的重要平台，适合相关领域研究者投稿。
Stability and Efficacy of Medicines Beyond Their Expiration Dates: A Systematic Review
2026-06-03T14:21:35Z
Simulation-Calibrated Control of Type I Error Rate in One-Trial Approach with Dose Optimization in Oncology Drug Development
2026-05-28T18:41:38Z
Pharmacoeconomic Evaluation of Netupitant Palonosetron for Chemotherapy-Induced Nausea and Vomiting: Evidence from Economic Analyses
2026-05-28T13:07:26Z
Arbitrated Indirect Treatment Comparisons
2026-05-23T18:15:11Z
Interpreting Non-Inferiority Across Effect Scales: A Bayesian Perspective with Clinical Translation
2026-05-14T13:00:01Z
Accelerating Global Access for Indication Extension Through Regulatory Reliance Pilot: The First Indication Extension Pilot in Oncology
2026-05-13T14:01:34Z
Evaluation of Ease of Use for Pediatric Medications Requiring Decapsulation, Dissolution, or Partial Dosing: A Questionnaire-Based Study in Japan
2026-05-13T17:06:08Z
Impact of Japanese Subpopulation Data and Overall Survival in Pivotal Trials on Oncology Drug Approvals in Japan
2026-05-12T14:43:13Z
Dasatinib-Associated Chylothorax: A Scoping Review and Pharmacovigilance Analysis
2026-05-11T17:12:39Z
Therapeutic Horizon in Multiple Myeloma: Analysis of the Emerging Landscape of Clinical Trials
2026-05-07T17:32:42Z
Advancing Wider Implementation of Multi-regional Clinical Trials in East Asia
2026-05-05T13:46:23Z
Pharmacovigilance Data From Digital Health Systems: Regulations, Implications, and Opportunities—A TransCelerate Perspective
2026-05-04T13:15:49Z
Analyses of U.S. FDA GCP Assessments and Recommendations for Marketing Applications, 2015–2024
2026-04-30T17:15:00Z
Comparative Assessment of the Pharmaceutical Quality of Amoxicillin Capsules Marketed in Authorized and an Unregulated Point of Sale in Mexican Market
2026-04-28T13:24:35Z
Training Needs Assessment and Capacity Building of Clinical Trial Assessors and Ethical Reviewers to Strengthen Regulatory Review in Tanzania
2026-04-27T01:27:29Z
Development of a Novel Risk Assessment Scale to Improve the Consistency and Reliability of Risk-Based Approaches in Clinical Trials
2026-04-27T01:29:40Z
Why MASLD Trials Underselect the MENA Region Sites and What Sponsors and Regulators Must Change
2026-04-25T17:43:06Z
Clinicians’ Reactions to Point-of-Care Advertising in Electronic Health Records
2026-04-25T17:33:39Z
